Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Alex Sparreboom" Clear advanced filters

  • Evidence indicates that reductions in recommended doses of chemotherapy often occur among obese patients with cancer. ASCO guidelines recommend that chemotherapy dosing in obese patients should be calculated based on actual weight, rather than the current practice based on estimation of body surface area. In this Review, chemotherapy dosing in this population is discussed along with how future research could lead to a more-personalized approach.

    • Gary H. Lyman
    • Alex Sparreboom
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 451-459

  • Identification of the optimal dose remains a key challenge in drug development. The standard approach that is based on identifying the maximum tolerated dose does not take into account important aspects of clinical pharmacology for newer targeted agents. The authors discuss adaptations to dose-finding trials for molecularly-targeted agents that enable more-efficient trials in the future in terms of costs and, most importantly, optimal patient benefit.

    • Ron H. J. Mathijssen
    • Alex Sparreboom
    • Jaap Verweij
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 272-281